Early Signals

Consumer nutrition is shifting toward closed-loop, data-driven systems, with Nu Skin’s Prysm iO signalling the emergence of real-time diagnostics integrated directly into personalised supplement ecosystems. This is an early signal of nutrition evolving into a measurable, feedback-driven infrastructure rather than a static product category.

AI-powered digital twins are entering nutrition formulation, enabling rapid, microbiome-driven product design with clinical grounding. As highlighted by Enbiosis 2.0, this is an early signal of a shift from product-led innovation to infrastructure-led formulation systems.

eMed’s (backed by Tom Brady) raise is an early signal that investor conviction is moving toward the service and orchestration layer around GLP 1s, especially where AI, employer benefits, clinical support, and at home care delivery converge. The supporting signal is the company’s explicit plan to use the capital to expand agentic AI and fund employer models tied to ongoing GLP 1 access and support.

A series of recent clinical studies across hypertension, lipid management, and biomarker research signal a coordinated shift toward earlier, more precise cardiometabolic prevention, where intervention is driven by underlying biology and risk stratification rather than late-stage disease presentation.

Consumer analysis from Clootrack suggests GLP-1 users are shifting purchasing behaviour toward symptom-driven “purchase rhythms,” signalling that demand is reorganising around physiological states rather than fixed product categories.

A new Karolinska Institutet study published in JAMA Network Open suggests dementia risk linked to diet varies by APOE genotype, signalling that brain-health nutrition could shift from generalised guidance to genotype-specific intervention.